|
EP2449112A1
(en)
|
2009-07-01 |
2012-05-09 |
Transposagen Biopharmaceuticals, Inc. |
Genetically modified rat models for severe combined immunodeficiency (scid)
|
|
BR112013024337A2
(pt)
|
2011-03-23 |
2017-09-26 |
Du Pont |
locus de traço transgênico complexo em uma planta, planta ou semente, método para produzir em uma planta um locus de traço transgênico complexo e construto de expressão
|
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
WO2013139861A1
(en)
|
2012-03-20 |
2013-09-26 |
Luc Montagnier |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
|
PL4289948T3
(pl)
|
2012-05-25 |
2025-06-02 |
The Regents Of The University Of California |
Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
HUE051612T2
(hu)
|
2012-07-11 |
2021-03-01 |
Sangamo Therapeutics Inc |
Eljárások és készítmények lizoszomális tárolási betegségek kezelésére
|
|
KR20230065381A
(ko)
*
|
2012-07-25 |
2023-05-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
|
|
EP2912175B1
(en)
|
2012-10-23 |
2018-08-22 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
CN105142669B
(zh)
|
2012-12-06 |
2018-07-03 |
西格马-奥尔德里奇有限责任公司 |
基于crispr的基因组修饰和调控
|
|
CN105658796B
(zh)
|
2012-12-12 |
2021-10-26 |
布罗德研究所有限公司 |
用于序列操纵的crispr-cas组分系统、方法以及组合物
|
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
PT2898075E
(pt)
*
|
2012-12-12 |
2016-06-16 |
Harvard College |
Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
WO2014093655A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
PL2784162T3
(pl)
|
2012-12-12 |
2016-01-29 |
Broad Inst Inc |
Opracowanie systemów, metod oraz zoptymalizowanych kompozycji przewodnikowych do manipulacji sekwencyjnej
|
|
EP4282970A3
(en)
|
2012-12-17 |
2024-01-17 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
|
AU2014207618A1
(en)
|
2013-01-16 |
2015-08-06 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
AU2014218931C1
(en)
|
2013-02-20 |
2020-05-14 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
|
KR20170108172A
(ko)
|
2013-03-14 |
2017-09-26 |
카리부 바이오사이언시스 인코포레이티드 |
핵산-표적화 핵산의 조성물 및 방법
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
IL289396B2
(en)
|
2013-03-15 |
2023-12-01 |
The General Hospital Coporation |
Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
|
CA2908697C
(en)
|
2013-04-16 |
2023-12-12 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
|
US20160186208A1
(en)
*
|
2013-04-16 |
2016-06-30 |
Whitehead Institute For Biomedical Research |
Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
|
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
|
CA2913869C
(en)
*
|
2013-05-29 |
2023-01-24 |
Cellectis |
New compact scaffold of cas9 in the type ii crispr system
|
|
WO2014194190A1
(en)
*
|
2013-05-30 |
2014-12-04 |
The Penn State Research Foundation |
Gene targeting and genetic modification of plants via rna-guided genome editing
|
|
KR20240172759A
(ko)
|
2013-06-17 |
2024-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
간의 표적화 및 치료를 위한 ＣＲＩＳＰＲＣａｓ 시스템, 벡터 및 조성물의 전달 및 용도
|
|
EP3597755A1
(en)
|
2013-06-17 |
2020-01-22 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
EP3674411A1
(en)
|
2013-06-17 |
2020-07-01 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
CA2915837A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
|
AU2014287397B2
(en)
|
2013-07-10 |
2019-10-10 |
President And Fellows Of Harvard College |
Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
|
|
US11306328B2
(en)
|
2013-07-26 |
2022-04-19 |
President And Fellows Of Harvard College |
Genome engineering
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
MX363842B
(es)
*
|
2013-08-22 |
2019-04-05 |
Du Pont |
Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
EP3038661B1
(en)
|
2013-08-29 |
2023-12-27 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for rna-guided treatment of hiv infection
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
EP3418379B1
(en)
|
2013-09-18 |
2020-12-09 |
Kymab Limited |
Methods, cells & organisms
|
|
WO2015054507A1
(en)
|
2013-10-10 |
2015-04-16 |
Pronutria, Inc. |
Nutritive polypeptide production systems, and methods of manufacture and use thereof
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
JP2016536021A
(ja)
|
2013-11-07 |
2016-11-24 |
エディタス・メディシン，インコーポレイテッド |
ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
|
|
WO2015071474A2
(en)
*
|
2013-11-18 |
2015-05-21 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
|
US9074199B1
(en)
*
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
|
SG10201700961TA
(en)
|
2013-12-11 |
2017-04-27 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
|
EP3080260B1
(en)
|
2013-12-12 |
2019-03-06 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
|
WO2015089354A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
JP2017501149A
(ja)
|
2013-12-12 |
2017-01-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
|
|
EP3653229A1
(en)
|
2013-12-12 |
2020-05-20 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
CN105899658B
(zh)
|
2013-12-12 |
2020-02-18 |
布罗德研究所有限公司 |
针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
DE212015000061U1
(de)
|
2014-02-11 |
2017-09-03 |
The Regents Of The University Of Colorado, A Body Corporate |
CRISPR-ermöglichtes Multiplex Genom Engineering
|
|
KR20160130392A
(ko)
*
|
2014-02-18 |
2016-11-11 |
듀크 유니버시티 |
바이러스 복제의 불활성화를 위한 조성물 및 그의 제조 및 사용 방법
|
|
EP3110971B1
(en)
|
2014-02-27 |
2019-05-08 |
The Broad Institute Inc. |
T cell balance gene expression and methods of use thereof
|
|
WO2015131101A1
(en)
|
2014-02-27 |
2015-09-03 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
ES2745769T3
(es)
|
2014-03-10 |
2020-03-03 |
Editas Medicine Inc |
Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
WO2015148863A2
(en)
|
2014-03-26 |
2015-10-01 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
EP4123024B1
(en)
*
|
2014-04-01 |
2024-12-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
|
US12460231B2
(en)
|
2014-04-02 |
2025-11-04 |
Editas Medicine, Inc. |
Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
|
|
SI3888674T1
(sl)
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
EP3129485B2
(en)
|
2014-04-09 |
2022-12-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
US20170175128A1
(en)
*
|
2014-04-18 |
2017-06-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
BR112016028023A2
(pt)
|
2014-05-30 |
2017-08-22 |
Univ Leland Stanford Junior |
Composições e métodos de administração de tratamentos para infecções virais latentes
|
|
HUE049776T2
(hu)
|
2014-06-06 |
2020-10-28 |
Regeneron Pharma |
Módszerek és készítmények egy célzott lókusz módosítására
|
|
JP6779866B2
(ja)
|
2014-06-13 |
2020-11-04 |
チルドレンズ メディカル センター コーポレイション |
ミトコンドリアを単離するための製品および方法
|
|
KR102425438B1
(ko)
|
2014-06-23 |
2022-07-27 |
더 제너럴 하스피탈 코포레이션 |
서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq)
|
|
EP3161128B1
(en)
|
2014-06-26 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
WO2016007347A1
(en)
|
2014-07-11 |
2016-01-14 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
CA2955203C
(en)
*
|
2014-07-14 |
2022-01-04 |
Washington State University |
Nanos knock-out that ablates germline cells
|
|
CN104152414B
(zh)
*
|
2014-07-18 |
2018-03-13 |
中国科学院广州生物医药与健康研究院 |
对细胞基因组的预定位点进行基因改造的方法
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
WO2016021973A1
(ko)
*
|
2014-08-06 |
2016-02-11 |
주식회사 툴젠 |
캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
|
|
JP6837429B2
(ja)
*
|
2014-08-11 |
2021-03-03 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
Ｃｒｉｓｐｒ／ｃａｓ９媒介遺伝子編集による筋ジストロフィーの予防
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
EP3686279B1
(en)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Genome editing using cas9 nickases
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
AU2015308910B2
(en)
|
2014-08-27 |
2017-12-07 |
Caribou Biosciences, Inc. |
Methods for increasing Cas9-mediated engineering efficiency
|
|
US10570418B2
(en)
|
2014-09-02 |
2020-02-25 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification
|
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
|
US10040048B1
(en)
|
2014-09-25 |
2018-08-07 |
Synthego Corporation |
Automated modular system and method for production of biopolymers
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
CN104546931B
(zh)
*
|
2014-09-30 |
2019-04-09 |
深圳华大基因科技有限公司 |
华德萨特氏菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
|
|
WO2016054225A1
(en)
*
|
2014-09-30 |
2016-04-07 |
Stc.Unm |
Plasmid delivery in the treatment of cancer and other disease states
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
US10583201B2
(en)
*
|
2014-10-10 |
2020-03-10 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
EP3212788A2
(en)
|
2014-10-27 |
2017-09-06 |
The Broad Institute, Inc. |
Compositions, methods and use of synthetic lethal screening
|
|
US12180263B2
(en)
|
2014-11-06 |
2024-12-31 |
President And Fellows Of Harvard College |
Cells lacking B2M surface expression and methods for allogeneic administration of such cells
|
|
US11680268B2
(en)
|
2014-11-07 |
2023-06-20 |
Editas Medicine, Inc. |
Methods for improving CRISPR/Cas-mediated genome-editing
|
|
US10858662B2
(en)
|
2014-11-19 |
2020-12-08 |
Institute For Basic Science |
Genome editing with split Cas9 expressed from two vectors
|
|
WO2016080399A1
(ja)
*
|
2014-11-20 |
2016-05-26 |
国立大学法人京都大学 |
哺乳動物の標的ゲノム領域にｄｎａをノックインする方法及び細胞
|
|
EP3221457B1
(en)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
WO2016086197A1
(en)
|
2014-11-25 |
2016-06-02 |
The Brigham And Women's Hospital, Inc. |
Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
|
|
US20180057839A1
(en)
|
2014-11-26 |
2018-03-01 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
CN113699116A
(zh)
|
2014-12-10 |
2021-11-26 |
明尼苏达大学董事会 |
用于治疗疾病的遗传修饰的细胞、组织和器官
|
|
WO2016094880A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
EP3230452B1
(en)
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
EP3786296A1
(en)
*
|
2014-12-18 |
2021-03-03 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
JP6840077B2
(ja)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
|
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
PL3193901T3
(pl)
|
2014-12-23 |
2018-10-31 |
4D Pharma Research Limited |
Polipeptyd pyrynowy i immunomodulacja
|
|
CN113862175A
(zh)
|
2014-12-23 |
2021-12-31 |
4D制药研究有限公司 |
免疫调控
|
|
CN107109427B
(zh)
|
2014-12-23 |
2021-06-18 |
先正达参股股份有限公司 |
用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
CA2970370A1
(en)
|
2014-12-24 |
2016-06-30 |
Massachusetts Institute Of Technology |
Crispr having or associated with destabilization domains
|
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
|
EP3250689B1
(en)
|
2015-01-28 |
2020-11-04 |
The Regents of The University of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
LT3250691T
(lt)
|
2015-01-28 |
2023-09-11 |
Caribou Biosciences, Inc. |
Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai
|
|
US20180245073A1
(en)
*
|
2015-02-23 |
2018-08-30 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3262193A2
(en)
|
2015-02-26 |
2018-01-03 |
The Broad Institute Inc. |
T cell balance gene expression, compositions of matters and methods of use thereof
|
|
WO2016138574A1
(en)
|
2015-03-02 |
2016-09-09 |
Sinai Health System |
Homologous recombination factors
|
|
WO2016141224A1
(en)
|
2015-03-03 |
2016-09-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
US10450576B2
(en)
|
2015-03-27 |
2019-10-22 |
E I Du Pont De Nemours And Company |
Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
|
|
WO2016161380A1
(en)
*
|
2015-04-01 |
2016-10-06 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
|
KR102888521B1
(ko)
*
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP4019975A1
(en)
|
2015-04-24 |
2022-06-29 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
WO2016183438A1
(en)
*
|
2015-05-14 |
2016-11-17 |
Massachusetts Institute Of Technology |
Self-targeting genome editing system
|
|
BR112017024534A2
(pt)
*
|
2015-05-15 |
2018-07-24 |
Pioneer Hi Bred Int |
sistemas de rna-guia/endonuclease cas9 inovadores
|
|
CA3000182A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Agenovir Corporation |
Methods and compositions for treating cells for transplant
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
MX2017015582A
(es)
|
2015-06-01 |
2018-09-06 |
Univ Temple |
Metodos y composiciones para tratamiento guiado por arn de infeccion por vih.
|
|
WO2016196655A1
(en)
|
2015-06-03 |
2016-12-08 |
The Regents Of The University Of California |
Cas9 variants and methods of use thereof
|
|
CN108368502B
(zh)
|
2015-06-03 |
2022-03-18 |
内布拉斯加大学董事委员会 |
使用单链dna的dna编辑
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
MA41060B1
(fr)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
MD3206700T2
(ro)
|
2015-06-15 |
2019-12-31 |
4D Pharma Res Ltd |
Compoziții conținând tulpini bacteriene
|
|
RS59446B1
(sr)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
|
|
PE20180267A1
(es)
|
2015-06-15 |
2018-02-06 |
4D Pharma Res Ltd |
Composiciones que comprenden cepas bacterianas
|
|
MA41010B1
(fr)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
|
AU2016278959A1
(en)
|
2015-06-17 |
2018-01-18 |
The Uab Research Foundation |
CRISPR/Cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
JP2018518182A
(ja)
|
2015-06-17 |
2018-07-12 |
ザ ユーエービー リサーチ ファンデーション |
ゲノム編集のためのｃｒｉｓｐｒ／ｃａｓ９複合体
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
EP4159856A1
(en)
|
2015-06-18 |
2023-04-05 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
MX392008B
(es)
*
|
2015-06-18 |
2025-03-21 |
Broad Inst Inc |
Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
|
|
US11414657B2
(en)
|
2015-06-29 |
2022-08-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
US10456452B2
(en)
|
2015-07-02 |
2019-10-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
|
|
US20170000743A1
(en)
*
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
IL295616A
(en)
|
2015-07-31 |
2022-10-01 |
Us Health |
Adapted cells and treatment methods
|
|
US9580727B1
(en)
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
WO2017027810A2
(en)
|
2015-08-12 |
2017-02-16 |
The General Hospital Corporation |
Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
|
|
WO2017027910A1
(en)
|
2015-08-14 |
2017-02-23 |
The University Of Sydney |
Connexin 45 inhibition for therapy
|
|
AU2016308339A1
(en)
|
2015-08-18 |
2018-04-12 |
Baylor College Of Medicine |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
WO2017040348A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
IL241462A0
(en)
|
2015-09-10 |
2015-11-30 |
Yeda Res & Dev |
Heterologous engineering of betalain pigments in plants
|
|
WO2017044843A1
(en)
|
2015-09-11 |
2017-03-16 |
The General Hospital Corporation |
Full interrogation of nuclease dsbs and sequencing (find-seq)
|
|
EP3786294A1
(en)
|
2015-09-24 |
2021-03-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
US20170088828A1
(en)
*
|
2015-09-29 |
2017-03-30 |
Agenovir Corporation |
Compositions and methods for treatment of latent viral infections
|
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
|
EP3356520B1
(en)
|
2015-10-02 |
2022-03-23 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
|
WO2017069958A2
(en)
|
2015-10-09 |
2017-04-27 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017070605A1
(en)
|
2015-10-22 |
2017-04-27 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
|
WO2017070598A1
(en)
|
2015-10-23 |
2017-04-27 |
Caribou Biosciences, Inc. |
Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
|
|
EP4434589A3
(en)
|
2015-10-23 |
2025-05-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075294A1
(en)
|
2015-10-28 |
2017-05-04 |
The Board Institute Inc. |
Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
|
|
WO2017075265A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute, Inc. |
Multiplex analysis of single cell constituents
|
|
EP4036228A1
(en)
|
2015-11-13 |
2022-08-03 |
Avellino Lab USA, Inc. |
Methods for the treatment of corneal dystrophies
|
|
WO2017087885A1
(en)
|
2015-11-19 |
2017-05-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
|
WO2017085520A1
(en)
|
2015-11-20 |
2017-05-26 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
|
EP4163374A1
(en)
*
|
2015-11-23 |
2023-04-12 |
The Regents of the University of California |
Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
|
|
WO2017095960A1
(en)
*
|
2015-11-30 |
2017-06-08 |
Synthetic Genomics, Inc. |
Compositions and methods for expressing genes in algae
|
|
WO2017095946A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes
|
|
WO2017093370A1
(en)
*
|
2015-12-03 |
2017-06-08 |
Technische Universität München |
T-cell specific genome editing
|
|
RU2018117360A
(ru)
|
2015-12-04 |
2020-01-09 |
Карибо Биосайенсиз, Инк. |
Сконструированные нуклеиновые кислоты, нацеленные на нуклеиновую кислоту
|
|
US11208649B2
(en)
|
2015-12-07 |
2021-12-28 |
Zymergen Inc. |
HTP genomic engineering platform
|
|
KR20180084756A
(ko)
|
2015-12-07 |
2018-07-25 |
지머젠 인코포레이티드 |
코리네박테리움 글루타미컴으로부터의 프로모터
|
|
US9988624B2
(en)
|
2015-12-07 |
2018-06-05 |
Zymergen Inc. |
Microbial strain improvement by a HTP genomic engineering platform
|
|
US12110490B2
(en)
|
2015-12-18 |
2024-10-08 |
The Broad Institute, Inc. |
CRISPR enzymes and systems
|
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
|
US11672866B2
(en)
|
2016-01-08 |
2023-06-13 |
Paul N. DURFEE |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
|
MX2018008344A
(es)
|
2016-01-11 |
2018-12-06 |
Univ Leland Stanford Junior |
Proteinas quimericas y metodos para regular la expresion genica.
|
|
JP7012645B2
(ja)
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
キメラタンパク質および免疫治療の方法
|
|
FI4272834T3
(fi)
|
2016-01-15 |
2025-12-05 |
Childrens Medical Ct Corp |
Mitokondrioiden ja yhdistettyjen mitokondriaalisten aineiden terapeuttinen käyttö
|
|
US10876129B2
(en)
|
2016-02-12 |
2020-12-29 |
Ceres, Inc. |
Methods and materials for high throughput testing of mutagenized allele combinations
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
EP3420102B1
(en)
|
2016-02-22 |
2024-04-03 |
Massachusetts Institute of Technology |
Methods for identifying and modulating immune phenotypes
|
|
CN105543196A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VRER及其编码基因与应用
|
|
CN105543195A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VQR及其编码基因与应用
|
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
|
JP6441536B2
(ja)
|
2016-03-04 |
2018-12-19 |
フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ |
細菌株を含む組成物
|
|
EP3423083A4
(en)
|
2016-03-04 |
2019-10-02 |
Indoor Biotechnologies Inc. |
FEL-D-1 KNOCKOUTS AND ASSOCIATED COMPOSITIONS AND METHODS BASED ON CRISPR-CAS9 GENERALIZATION
|
|
JP2019515654A
(ja)
|
2016-03-16 |
2019-06-13 |
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ |
肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
WO2017161325A1
(en)
|
2016-03-17 |
2017-09-21 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
|
US20200291370A1
(en)
*
|
2016-03-18 |
2020-09-17 |
President And Fellows Of Harvard College |
Mutant Cas Proteins
|
|
WO2017165859A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
KR20260004568A
(ko)
|
2016-04-19 |
2026-01-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
WO2017189308A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
CN107304435A
(zh)
*
|
2016-04-22 |
2017-10-31 |
中国科学院青岛生物能源与过程研究所 |
一种Cas9/RNA系统及其应用
|
|
ES2865481T3
(es)
|
2016-04-29 |
2021-10-15 |
Poseida Therapeutics Inc |
Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
KR20190019168A
(ko)
|
2016-06-17 |
2019-02-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
제vi형 crispr 오솔로그 및 시스템
|
|
CN109688820B
(zh)
|
2016-06-24 |
2023-01-10 |
科罗拉多州立大学董事会（法人团体） |
用于生成条形码化组合文库的方法
|
|
EP3474849B1
(en)
|
2016-06-27 |
2025-05-21 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
KR102345899B1
(ko)
|
2016-06-30 |
2021-12-31 |
지머젠 인코포레이티드 |
박테리아 헤모글로빈 라이브러리를 생성하는 방법 및 이의 용도
|
|
JP2019519241A
(ja)
|
2016-06-30 |
2019-07-11 |
ザイマージェン インコーポレイテッド |
グルコース透過酵素ライブラリーを生成するための方法およびその使用
|
|
AU2017295720B2
(en)
|
2016-07-13 |
2021-07-22 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
TW201821093A
(zh)
|
2016-07-13 |
2018-06-16 |
英商４Ｄ製藥有限公司 |
包含細菌菌株之組合物
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
CA3032822A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
ES2998057T3
(en)
*
|
2016-08-12 |
2025-02-18 |
Toolgen Inc |
Manipulated immunoregulatory element and immunity altered thereby
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
|
US12431216B2
(en)
|
2016-08-17 |
2025-09-30 |
Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
WO2018034554A1
(ko)
*
|
2016-08-19 |
2018-02-22 |
주식회사 툴젠 |
인위적으로 조작된 신생혈관형성 조절 시스템
|
|
WO2020225754A1
(en)
|
2019-05-06 |
2020-11-12 |
Mcmullen Tara |
Crispr gene editing for autosomal dominant diseases
|
|
CN109963945A
(zh)
|
2016-08-20 |
2019-07-02 |
阿维利诺美国实验室股份有限公司 |
单一向导rna、crispr/cas9系统及其使用方法
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
JP7215994B2
(ja)
|
2016-09-06 |
2023-01-31 |
ザ チルドレンズ メディカル センター コーポレーション |
人工多能性幹細胞由来の免疫細胞
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
EP4431607A3
(en)
|
2016-09-09 |
2024-12-11 |
The Board of Trustees of the Leland Stanford Junior University |
High-throughput precision genome editing
|
|
IL247752A0
(en)
|
2016-09-11 |
2016-11-30 |
Yeda Res & Dev |
Compositions and methods for modulating gene expression for site-directed mutagenesis
|
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
|
WO2018064208A1
(en)
|
2016-09-28 |
2018-04-05 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
US20190203230A1
(en)
|
2016-09-28 |
2019-07-04 |
Novartis Ag |
Porous membrane-based macromolecule delivery system
|
|
JP2019532644A
(ja)
|
2016-09-30 |
2019-11-14 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｒｎａ誘導型核酸修飾酵素及びその使用方法
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
AU2017342543B2
(en)
*
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
US20190256868A1
(en)
*
|
2016-10-28 |
2019-08-22 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
CA3042259A1
(en)
|
2016-11-04 |
2018-05-11 |
Flagship Pioneering Innovations V. Inc. |
Novel plant cells, plants, and seeds
|
|
US12227578B2
(en)
|
2016-11-11 |
2025-02-18 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
|
|
US9816093B1
(en)
|
2016-12-06 |
2017-11-14 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
|
WO2018107103A1
(en)
|
2016-12-09 |
2018-06-14 |
The Broad Institute, Inc. |
Crispr-systems for modifying a trait of interest in a plant
|
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
|
US11674128B2
(en)
*
|
2016-12-12 |
2023-06-13 |
Tsinghua University |
Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
|
|
CA3045134A1
(en)
|
2016-12-14 |
2018-06-21 |
Ligandal, Inc. |
Compositions and methods for nucleic acid and/or protein payload delivery
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
US12241074B2
(en)
|
2016-12-22 |
2025-03-04 |
Monsanto Technology Llc |
Genome editing-based crop engineering and production of brachytic plants
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
WO2018129368A2
(en)
|
2017-01-06 |
2018-07-12 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
FI3565891T3
(fi)
|
2017-01-09 |
2023-07-04 |
Whitehead Inst Biomedical Res |
Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3573448A4
(en)
|
2017-01-28 |
2020-09-02 |
Inari Agriculture, Inc. |
NEW PLANT CELLS, PLANTS AND SEEDS
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
CN110312797A
(zh)
|
2017-02-10 |
2019-10-08 |
齐默尔根公司 |
组装和编辑用于多个宿主的多个dna构建体的模块化通用质粒设计策略
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US11344629B2
(en)
|
2017-03-01 |
2022-05-31 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
|
EP3589751A4
(en)
|
2017-03-03 |
2021-11-17 |
The Regents of The University of California |
RNA TARGETING OF MUTATIONS VIA SUPPRESSOR RNA AND DEAMINASES
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CN120330163A
(zh)
|
2017-03-15 |
2025-07-18 |
博德研究所 |
新型cas13b直向同源物crispr酶和系统
|
|
WO2018170515A1
(en)
|
2017-03-17 |
2018-09-20 |
The Broad Institute, Inc. |
Methods for identifying and modulating co-occurant cellular phenotypes
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US12161694B2
(en)
|
2017-03-24 |
2024-12-10 |
The Broad Institute, Inc. |
Methods and compositions for regulating innate lymphoid cell inflammatory responses
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
CA3059757A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Institute Of Technology |
Novel type vi crispr orthologs and systems
|
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
|
MX2019012398A
(es)
|
2017-04-18 |
2020-09-25 |
Broad Inst Inc |
Composiciones para detectar secreciones y metodos de uso.
|
|
US12058986B2
(en)
|
2017-04-20 |
2024-08-13 |
Egenesis, Inc. |
Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
BR112019021719A2
(pt)
|
2017-04-21 |
2020-06-16 |
The General Hospital Corporation |
Variantes de cpf1 (cas12a) com especificidade para pam alterada
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615672A1
(en)
|
2017-04-28 |
2020-03-04 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
AU2018264636B2
(en)
*
|
2017-05-08 |
2022-03-17 |
Toolgen Incorporated |
Artificially manipulated immune cell
|
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
EP3622062A4
(en)
|
2017-05-10 |
2020-10-14 |
The Regents of the University of California |
DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US11692184B2
(en)
|
2017-05-16 |
2023-07-04 |
The Regents Of The University Of California |
Thermostable RNA-guided endonucleases and methods of use thereof
|
|
WO2018213726A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
JP7364472B2
(ja)
|
2017-05-18 |
2023-10-18 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化された核酸編集のための系、方法、及び組成物
|
|
HUE054164T2
(hu)
|
2017-05-22 |
2021-08-30 |
4D Pharma Res Ltd |
Baktériumtörzseket tartalmazó készítmények
|
|
WO2018215782A1
(en)
|
2017-05-24 |
2018-11-29 |
4D Pharma Research Limited |
Compositions comprising bacterial strain
|
|
EP3630970A4
(en)
|
2017-05-25 |
2020-12-30 |
The General Hospital Corporation |
BASIC EDITORS WITH IMPROVED PRECISION AND SPECIFICITY
|
|
US20200263186A1
(en)
*
|
2017-05-26 |
2020-08-20 |
North Carolina State University |
Altered guide rnas for modulating cas9 activity and methods of use
|
|
EP3409104A1
(en)
|
2017-05-31 |
2018-12-05 |
Vilmorin et Cie |
Tomato plant resistant to tomato yellow leaf curl virus, powdery mildew, and nematodes
|
|
EP3409106A1
(en)
|
2017-06-01 |
2018-12-05 |
Vilmorin et Cie |
Tolerance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus (tbrfv)
|
|
WO2020249996A1
(en)
|
2019-06-14 |
2020-12-17 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus
|
|
US11603544B2
(en)
|
2017-06-05 |
2023-03-14 |
Fred Hutchinson Cancer Center |
Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
|
|
US12338449B2
(en)
|
2017-06-05 |
2025-06-24 |
Research Institute At Nationwide Children's Hospital |
Enhanced modified viral capsid proteins
|
|
WO2018226900A2
(en)
|
2017-06-06 |
2018-12-13 |
Zymergen Inc. |
A htp genomic engineering platform for improving fungal strains
|
|
EP3878961A1
(en)
|
2017-06-06 |
2021-09-15 |
Zymergen, Inc. |
A htp genomic engineering platform for improving escherichia coli
|
|
AU2018279112B2
(en)
*
|
2017-06-07 |
2024-11-07 |
Arc Bio, Llc |
Creation and use of guide nucleic acids
|
|
EP3635104A1
(en)
|
2017-06-09 |
2020-04-15 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
AU2018285860A1
(en)
|
2017-06-13 |
2020-01-02 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
LT3600363T
(lt)
|
2017-06-14 |
2021-02-10 |
4D Pharma Research Limited |
Kompozicijos, apimančios bakterijų kamienus
|
|
SMT202000695T1
(it)
|
2017-06-14 |
2021-01-05 |
4D Pharma Res Limited |
Composizioni comprendenti ceppi batterici
|
|
MA49010B1
(fr)
|
2017-06-14 |
2020-11-30 |
4D Pharma Res Ltd |
Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
|
|
CA3065326A1
(en)
|
2017-06-14 |
2018-12-20 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
AU2018290843B2
(en)
|
2017-06-26 |
2025-04-24 |
Massachusetts Institute Of Technology |
CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
|
EP3654993A4
(en)
|
2017-07-17 |
2021-08-25 |
The Broad Institute, Inc. |
CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
|
|
WO2019018551A2
(en)
|
2017-07-18 |
2019-01-24 |
Lee Tzumin |
METHODS AND COMPOSITIONS FOR GENETICALLY GENETIC HANDLING OF GENES AND CELLS
|
|
WO2019018694A1
(en)
|
2017-07-19 |
2019-01-24 |
Dana-Farber Cancer Institute, Inc. |
DIAGNOSIS AND TREATMENT OF CANCER
|
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
TWI820034B
(zh)
|
2017-07-31 |
2023-11-01 |
香港商映像生物有限公司 |
眼部疾病之細胞模式及用於眼部疾病的療法
|
|
EP3672612A4
(en)
|
2017-08-23 |
2021-09-29 |
The General Hospital Corporation |
GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES WITH MODIFIED PAM SPECIFICITY
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
US11713452B2
(en)
|
2017-09-08 |
2023-08-01 |
University Of North Texas Health Science Center |
Engineered CAS9 variants
|
|
US20190076814A1
(en)
|
2017-09-11 |
2019-03-14 |
Synthego Corporation |
Biopolymer synthesis system and method
|
|
WO2019056099A1
(en)
|
2017-09-19 |
2019-03-28 |
The University Of British Columbia |
ANTI-HLA-A2 ANTIBODIES AND METHODS OF USE
|
|
IT201700105372A1
(it)
*
|
2017-09-20 |
2019-03-20 |
Fondazione St Italiano Tecnologia |
Molecola di acido nucleico funzionale e relativo uso
|
|
WO2019056106A1
(en)
|
2017-09-20 |
2019-03-28 |
The University Of British Columbia |
NOVEL ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
|
|
EP3684389A4
(en)
|
2017-09-21 |
2021-06-16 |
Dana Farber Cancer Institute, Inc. |
Isolation, preservation, compositions and uses of extracts from justicia plants
|
|
KR20200066616A
(ko)
|
2017-09-21 |
2020-06-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
|
|
EP3688168A4
(en)
|
2017-09-25 |
2021-07-14 |
Agrospheres, Inc. |
COMPOSITIONS AND METHODS FOR THE SCALABLE PRODUCTION AND RELEASE OF BIOLOGICS
|
|
US10933027B1
(en)
|
2017-09-25 |
2021-03-02 |
National Technology & Engineering Solutions Of Sandia, Llc |
Expanded pore particles and delivery methods thereof
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
WO2019071054A1
(en)
|
2017-10-04 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
|
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
|
US11680296B2
(en)
|
2017-10-16 |
2023-06-20 |
Massachusetts Institute Of Technology |
Mycobacterium tuberculosis host-pathogen interaction
|
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
CA3079681A1
(en)
|
2017-10-20 |
2019-04-25 |
Fred Hutchinson Cancer Research Center |
Systems and methods to produce b cells genetically modified to express selected antibodies
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
WO2019094984A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
JP7423520B2
(ja)
|
2017-11-16 |
2024-01-29 |
アストラゼネカ・アクチエボラーグ |
Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
|
|
CN111601883B
(zh)
|
2017-11-17 |
2024-06-21 |
艾欧凡斯生物治疗公司 |
由细针抽吸物和小活检物扩增til
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
|
|
US11332736B2
(en)
|
2017-12-07 |
2022-05-17 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
|
CN109912702B
(zh)
*
|
2017-12-13 |
2021-03-16 |
中国科学院遗传与发育生物学研究所 |
蛋白质OsARE1在调控植物抗低氮性中的应用
|
|
US11578323B2
(en)
|
2017-12-14 |
2023-02-14 |
Bayer Healthcare Llc |
RNA-programmable endonuclease systems and their use in genome editing and other applications
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US20230193242A1
(en)
|
2017-12-22 |
2023-06-22 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
WO2019133881A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for enginerering erythroid cells
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
US20200362366A1
(en)
|
2018-01-12 |
2020-11-19 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
|
BR112020014315A2
(pt)
|
2018-01-17 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Inibidores de dna-pk
|
|
EA202091709A1
(ru)
|
2018-01-17 |
2020-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы днк-пк
|
|
ES2940786T3
(es)
|
2018-01-17 |
2023-05-11 |
Vertex Pharma |
Compuestos de quinoxalinona, composiciones, métodos y kits para aumentar la eficiencia de edición del genoma
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
|
CN112153984A
(zh)
|
2018-01-30 |
2020-12-29 |
福宏治疗公司 |
化合物及其用途
|
|
EP3749764A1
(en)
|
2018-02-08 |
2020-12-16 |
Zymergen, Inc. |
Genome editing using crispr in corynebacterium
|
|
WO2019165168A1
(en)
|
2018-02-23 |
2019-08-29 |
Pioneer Hi-Bred International, Inc. |
Novel cas9 orthologs
|
|
EP3765614A1
(en)
|
2018-03-14 |
2021-01-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CA3092497A1
(en)
|
2018-03-19 |
2019-09-26 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and uses thereof
|
|
US20210155959A1
(en)
|
2018-04-06 |
2021-05-27 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
JP7447014B2
(ja)
|
2018-04-13 |
2024-03-11 |
サンガモ セラピューティクス フランス |
インターロイキン２３受容体に特異的なキメラ抗原受容体
|
|
WO2019204378A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
|
US12338486B2
(en)
|
2018-04-19 |
2025-06-24 |
Massachusetts Institute Of Technology |
Single-stranded break detection in double-stranded DNA
|
|
CN112334577B
(zh)
|
2018-04-19 |
2023-10-17 |
加利福尼亚大学董事会 |
用于基因编辑的组合物和方法
|
|
EP3560330B1
(en)
|
2018-04-24 |
2022-06-15 |
KWS SAAT SE & Co. KGaA |
Plants with improved digestibility and marker haplotypes
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
MA52533A
(fr)
|
2018-04-27 |
2021-03-03 |
Iovance Biotherapeutics Inc |
Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
|
|
JP7568511B2
(ja)
|
2018-04-27 |
2024-10-16 |
ジーンエディット インコーポレイテッド |
カチオン性ポリマーおよびその生体分子送達のための使用
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
US12281301B2
(en)
|
2018-04-27 |
2025-04-22 |
The Broad Institute, Inc. |
Sequencing-based proteomics
|
|
WO2019213660A2
(en)
|
2018-05-04 |
2019-11-07 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
|
CN112513271A
(zh)
|
2018-05-10 |
2021-03-16 |
奥克索利提克有限公司 |
使用营养缺陷型可调控细胞进行基因治疗的方法和组合物
|
|
CN112654710A
(zh)
|
2018-05-16 |
2021-04-13 |
辛瑟高公司 |
用于指导rna设计和使用的方法和系统
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12227776B2
(en)
|
2018-06-13 |
2025-02-18 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US11045554B1
(en)
|
2018-06-22 |
2021-06-29 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid-coated particles for treating viral infections
|
|
CA3101066A1
(en)
|
2018-06-26 |
2020-01-02 |
The Broad Institute, Inc. |
Crispr/cas and transposase based amplification compositions, systems and methods
|
|
US20210269866A1
(en)
|
2018-06-26 |
2021-09-02 |
The Broad Institute, Inc. |
Crispr effector system based amplification methods, systems, and diagnostics
|
|
AU2019291918B2
(en)
|
2018-06-29 |
2025-06-12 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
US11629179B2
(en)
|
2018-06-29 |
2023-04-18 |
Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis |
TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
CA3105658A1
(en)
|
2018-07-13 |
2020-01-16 |
The Regents Of The University Of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
|
WO2020028555A2
(en)
|
2018-07-31 |
2020-02-06 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
EP3833761A1
(en)
|
2018-08-07 |
2021-06-16 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
|
AU2019318135A1
(en)
|
2018-08-10 |
2021-03-04 |
Sangamo Therapeutics France |
New car constructs comprising TNFR2 domains
|
|
EP3607819A1
(en)
|
2018-08-10 |
2020-02-12 |
Vilmorin et Cie |
Resistance to xanthomonas campestris pv. campestris (xcc) in cauliflower
|
|
JP2021533773A
(ja)
|
2018-08-15 |
2021-12-09 |
ザイマージェン インコーポレイテッド |
ハイスループット代謝操作におけるＣＲＩＳＰＲｉの適用
|
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
WO2020041456A1
(en)
|
2018-08-22 |
2020-02-27 |
The Regents Of The University Of California |
Variant type v crispr/cas effector polypeptides and methods of use thereof
|
|
KR102712986B1
(ko)
|
2018-08-23 |
2024-10-07 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
|
WO2020047124A1
(en)
|
2018-08-28 |
2020-03-05 |
Flagship Pioneering, Inc. |
Methods and compositions for modulating a genome
|
|
US12545910B2
(en)
|
2018-08-31 |
2026-02-10 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
US12534743B2
(en)
|
2018-08-31 |
2026-01-27 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
US11479762B1
(en)
|
2018-08-31 |
2022-10-25 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
WO2020051507A1
(en)
|
2018-09-06 |
2020-03-12 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
|
EP3847251A1
(en)
|
2018-09-07 |
2021-07-14 |
Astrazeneca AB |
Compositions and methods for improved nucleases
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
|
|
JP7344300B2
(ja)
|
2018-09-18 |
2023-09-13 |
ブイエヌブイ ニューコ インク． |
Ａｒｃベースのカプシドおよびその使用
|
|
AU2019342197B2
(en)
|
2018-09-21 |
2025-10-16 |
President And Fellows Of Harvard College |
Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins
|
|
US12252708B2
(en)
|
2018-09-24 |
2025-03-18 |
Unm Rainforest Innovations |
Living mammalian cells modified with functional modular nanoparticles
|
|
WO2020067004A1
(ja)
*
|
2018-09-25 |
2020-04-02 |
公益財団法人微生物化学研究会 |
新規ウイルスベクターおよびその製造方法と使用方法
|
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
WO2020081808A1
(en)
*
|
2018-10-18 |
2020-04-23 |
Chan Zuckerberg Biohub, Inc. |
Methods and compositions involving thermostable cas9 protein variants
|
|
EP3867380A2
(en)
|
2018-10-18 |
2021-08-25 |
Intellia Therapeutics, Inc. |
Compositions and methods for expressing factor ix
|
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
US12116458B2
(en)
|
2018-10-24 |
2024-10-15 |
Genedit Inc. |
Cationic polymer with alkyl side chains and use for biomolecule delivery
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
JP2022513408A
(ja)
|
2018-10-31 |
2022-02-07 |
ザイマージェン インコーポレイテッド |
Ｄｎａライブラリーの多重化決定論的アセンブリー
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
KR20210091213A
(ko)
|
2018-11-05 |
2021-07-21 |
이오반스 바이오테라퓨틱스, 인크. |
종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
|
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
US20230039976A1
(en)
|
2018-11-05 |
2023-02-09 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
JP7688575B2
(ja)
|
2018-11-05 |
2025-06-04 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
抗ｐｄ－１抗体に対して不応性のｎｓｃｌｃ患者の治療
|
|
US12165743B2
(en)
|
2018-11-09 |
2024-12-10 |
The Broad Institute, Inc. |
Compressed sensing for screening and tissue imaging
|
|
US12402610B2
(en)
|
2018-11-09 |
2025-09-02 |
The Broad Institute, Inc. |
Methods and compositions for modulating innate lymphoid cell pathogenic effectors
|
|
AU2019374883A1
(en)
|
2018-11-09 |
2021-05-20 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
US12365888B2
(en)
|
2018-12-14 |
2025-07-22 |
Pioneer Hi-Bred International, Inc. |
CRISPR-Cas systems for genome editing
|
|
US12264323B2
(en)
|
2018-12-17 |
2025-04-01 |
The Broad Institute, Inc. |
CRISPR CPF1 direct repeat variants
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN113544266A
(zh)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
Crispr相关转座酶系统和其使用方法
|
|
EP3898947A1
(en)
|
2018-12-19 |
2021-10-27 |
King's College London |
Immunotherapeutic methods and compositions
|
|
US20220193131A1
(en)
|
2018-12-19 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
|
|
IL312708A
(en)
*
|
2018-12-27 |
2024-07-01 |
Lifeedit Therapeutics Inc |
Polypeptides useful for gene editing and methods of use
|
|
EP3906415A1
(en)
|
2019-01-03 |
2021-11-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020160100A1
(en)
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
|
US12460230B2
(en)
|
2019-02-10 |
2025-11-04 |
The J. David Gladstone Institutes |
Modified mitochondrion and methods of use thereof
|
|
WO2020168234A1
(en)
*
|
2019-02-14 |
2020-08-20 |
Metagenomi Ip Technologies, Llc |
Enzymes with ruvc domains
|
|
US10913941B2
(en)
|
2019-02-14 |
2021-02-09 |
Metagenomi Ip Technologies, Llc |
Enzymes with RuvC domains
|
|
JP2022520428A
(ja)
*
|
2019-02-14 |
2022-03-30 |
メタゲノミ アイピー テクノロジーズ，エルエルシー |
Ｒｕｖｃドメインを有する酵素
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
US12208164B2
(en)
|
2019-02-28 |
2025-01-28 |
Unm Rainforest Innovations |
Modular metal-organic polyhedra superassembly compositions
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
EP3935156A4
(en)
|
2019-03-07 |
2022-12-28 |
The Regents of The University of California |
CRISPR-CAS EFFECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
MX2021010840A
(es)
|
2019-03-08 |
2022-01-19 |
Obsidian Therapeutics Inc |
Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
|
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
|
WO2020185590A1
(en)
|
2019-03-08 |
2020-09-17 |
Zymergen Inc. |
Iterative genome editing in microbes
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
|
US20220162649A1
(en)
|
2019-04-01 |
2022-05-26 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
|
GB201905360D0
(en)
|
2019-04-16 |
2019-05-29 |
Univ Nottingham |
Fungal strains, production and uses thereof
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US20220340711A1
(en)
|
2019-04-23 |
2022-10-27 |
GenEdit, Inc. |
Cationic polymer with alkyl side chains
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
AU2020268959B2
(en)
|
2019-05-03 |
2026-02-19 |
Specific Biologics Inc. |
Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
UA128175C2
(uk)
|
2019-05-13 |
2024-04-24 |
Квс Саат Се Енд Ко. Кгаа |
Посухостійкість у кукурудзи
|
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP3969466A4
(en)
|
2019-05-14 |
2023-01-18 |
Yield10 Bioscience, Inc. |
MODIFIED PLANTS WITH A POLYNUCLEOTIDE WITH AN UNRELATED PROMOTER OPERATIONALLY LINKED TO AN CODING SEQUENCE THAT ENCODES A TRANSCRIPTION FACTOR
|
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
CA3141159A1
(en)
|
2019-05-21 |
2020-11-26 |
Sangamo Therapeutics, Inc. |
Controlled transgene expression in regulatory t cells
|
|
AR118995A1
(es)
|
2019-05-25 |
2021-11-17 |
Kws Saat Se & Co Kgaa |
Mejorador de la inducción de haploides
|
|
CA3142035A1
(en)
|
2019-05-28 |
2020-12-03 |
Genedit Inc. |
Polymer comprising multiple functionalized sidechains for biomolecule delivery
|
|
CN120718905A
(zh)
|
2019-05-29 |
2025-09-30 |
孟山都技术公司 |
使用基因组编辑产生显性等位基因的方法和组合物
|
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
|
WO2020244759A1
(en)
|
2019-06-05 |
2020-12-10 |
Klemm & Sohn Gmbh & Co. Kg |
New plants having a white foliage phenotype
|
|
WO2020254850A1
(en)
|
2019-06-21 |
2020-12-24 |
Vilmorin & Cie |
Improvement of quality and permanence of green color of peppers at maturity and over-maturity
|
|
MX2021014861A
(es)
|
2019-06-25 |
2022-06-22 |
Inari Agriculture Tech Inc |
Edicion genomica de reparacion dependiente de homologia mejorada.
|
|
SG11202111943UA
(en)
|
2019-07-02 |
2021-11-29 |
Hutchinson Fred Cancer Res |
Recombinant ad35 vectors and related gene therapy improvements
|
|
WO2021009299A1
(en)
|
2019-07-17 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
|
|
US11746354B2
(en)
|
2019-07-19 |
2023-09-05 |
Inari Agriculture Technology, Inc. |
Homology dependent repair genome editing
|
|
WO2021019272A1
(en)
|
2019-07-31 |
2021-02-04 |
Vilmorin & Cie |
Tolerance to tolcndv in cucumber
|
|
US12371695B2
(en)
|
2019-08-02 |
2025-07-29 |
Monsanto Technology Llc |
Methods and compositions to promote targeted genome modifications using HUH endonucleases
|
|
CN114245803A
(zh)
|
2019-08-06 |
2022-03-25 |
儿童医疗中心有限公司 |
用于重构小神经胶质细胞的方法和组合物
|
|
EP3772542A1
(en)
|
2019-08-07 |
2021-02-10 |
KWS SAAT SE & Co. KGaA |
Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
|
|
WO2021023307A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
复旦大学 |
CRISPR/Cas9基因编辑系统及其应用
|
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
CA3153563A1
(en)
*
|
2019-09-09 |
2021-03-18 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
|
EP4031660A1
(en)
|
2019-09-20 |
2022-07-27 |
The Broad Institute, Inc. |
Novel type vi crispr enzymes and systems
|
|
CA3147643A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression
|
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
AU2020368539A1
(en)
|
2019-10-16 |
2022-04-28 |
Massachusetts Institute Of Technology |
Engineered muscle targeting compositions
|
|
US20230357788A1
(en)
|
2019-10-17 |
2023-11-09 |
KWS SAAT SE & Co. KGaA |
Enhanced disease resistance of crops by downregulation of repressor genes
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
AU2020379046B2
(en)
|
2019-11-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy
|
|
IL292329A
(en)
*
|
2019-11-13 |
2022-06-01 |
Crispr Therapeutics Ag |
Manufacturing process for making t cells expressing chimeric antigen receptors
|
|
TW202132560A
(zh)
*
|
2019-11-13 |
2021-09-01 |
瑞士商Ｃｒｉｓｐｒ治療公司 |
製備car-t細胞之方法
|
|
WO2021094805A1
(en)
|
2019-11-14 |
2021-05-20 |
Vilmorin & Cie |
Resistance to acidovorax valerianellae in corn salad
|
|
US20240016735A1
(en)
|
2019-11-22 |
2024-01-18 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
CN115038789A
(zh)
|
2019-12-02 |
2022-09-09 |
塑造治疗公司 |
治疗性编辑
|
|
JP7749561B2
(ja)
|
2019-12-11 |
2025-10-06 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
|
|
EP4706689A2
(en)
|
2019-12-19 |
2026-03-11 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
IL271656A
(en)
|
2019-12-22 |
2021-06-30 |
Yeda Res & Dev |
System and methods for identifying cells that have undergone genome editing
|
|
CN116234906A
(zh)
|
2020-01-13 |
2023-06-06 |
萨那生物技术股份有限公司 |
血型抗原的修饰
|
|
CN115397974A
(zh)
|
2020-01-23 |
2022-11-25 |
儿童医疗中心有限公司 |
由人类多能干细胞进行无基质t细胞分化
|
|
US12312613B2
(en)
|
2020-01-24 |
2025-05-27 |
The General Hospital Corporation |
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
|
|
WO2021151085A2
(en)
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
|
JP7561195B2
(ja)
|
2020-01-29 |
2024-10-03 |
フォグホーン セラピューティクス インコーポレイテッド |
化合物及びその使用
|
|
EP3872190A1
(en)
|
2020-02-26 |
2021-09-01 |
Antibodies-Online GmbH |
A method of using cut&run or cut&tag to validate crispr-cas targeting
|
|
WO2021178717A2
(en)
|
2020-03-04 |
2021-09-10 |
Flagship Pioneering Innovations Vi, Llc |
Improved methods and compositions for modulating a genome
|
|
EP4118207A1
(en)
|
2020-03-11 |
2023-01-18 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
|
|
KR20230004510A
(ko)
|
2020-03-20 |
2023-01-06 |
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) |
인간 cd45rc에 특이적인 키메라 항원 수용체 및 이의 용도
|
|
ES3055163T3
(en)
|
2020-03-31 |
2026-02-10 |
Metagenomi Inc |
Class ii, type ii crispr systems
|
|
WO2021202938A1
(en)
|
2020-04-03 |
2021-10-07 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
|
US11433121B1
(en)
|
2020-04-03 |
2022-09-06 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid composition for the delivery of therapeutic cargos
|
|
US20230165909A1
(en)
|
2020-04-21 |
2023-06-01 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021217082A1
(en)
|
2020-04-23 |
2021-10-28 |
Genedit Inc. |
Polymer with cationic and hydrophobic side chains
|
|
WO2021215897A1
(ko)
*
|
2020-04-24 |
2021-10-28 |
기초과학연구원 |
Cas9 또는 cas9 변이체를 이용한 유전체 교정
|
|
CA3176826A1
(en)
|
2020-05-04 |
2021-11-11 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
WO2021224633A1
(en)
|
2020-05-06 |
2021-11-11 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
US12383555B2
(en)
|
2020-05-20 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancers
|
|
JP2023526670A
(ja)
|
2020-05-22 |
2023-06-22 |
インシトロ インコーポレイテッド |
機械学習モデルを使用した疾患の転帰の予測
|
|
JP2023527446A
(ja)
|
2020-05-29 |
2023-06-28 |
カー・ヴェー・エス ザート エス・エー ウント コー． カー・ゲー・アー・アー |
植物単数体の誘導
|
|
WO2021245435A1
(en)
|
2020-06-03 |
2021-12-09 |
Vilmorin & Cie |
Melon plants resistant to scab disease, aphids and powdery mildew
|
|
EP4161252A1
(en)
|
2020-06-05 |
2023-04-12 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the tobrfv
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
US20240011030A1
(en)
|
2020-08-10 |
2024-01-11 |
Novartis Ag |
Treatments for retinal degenerative diseases
|
|
EP4100028A4
(en)
|
2020-08-20 |
2023-07-26 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
EP4097486A4
(en)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
|
|
WO2022040444A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
JP7830442B2
(ja)
|
2020-10-02 |
2026-03-16 |
ビルモラン エ コンパニー |
貯蔵寿命が延長されたメロン
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
EP4243608A1
(en)
|
2020-11-11 |
2023-09-20 |
Leibniz-Institut für Pflanzenbiochemie (IPB) |
Fusion protein for editing endogenous dna of a eukaryotic cell
|
|
MX2023005609A
(es)
|
2020-11-13 |
2023-05-29 |
Novartis Ag |
Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
|
|
EP4001429A1
(en)
|
2020-11-16 |
2022-05-25 |
Antibodies-Online GmbH |
Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
|
|
WO2022117884A1
(en)
|
2020-12-03 |
2022-06-09 |
Vilmorin & Cie |
Tomato plants resistant to tobrfv, tmv, tomv and tommv and corresponding resistance genes
|
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
CA3206361A1
(en)
|
2020-12-23 |
2022-06-30 |
Flagship Pioneering Innovations V, Inc. |
In vitro assembly of anellovirus capsids enclosing rna
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
AU2022221606A1
(en)
|
2021-02-16 |
2023-08-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
GB202103131D0
(en)
|
2021-03-05 |
2021-04-21 |
Biosystems Tech Limited |
Method for preparation of research organisms
|
|
US20240191191A1
(en)
|
2021-03-19 |
2024-06-13 |
Iovance Biotherapeutics, Inc. |
Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
|
KR20240032711A
(ko)
|
2021-03-25 |
2024-03-12 |
이오반스 바이오테라퓨틱스, 인크. |
T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물
|
|
IL307298A
(en)
|
2021-03-31 |
2023-11-01 |
Entrada Therapeutics Inc |
Cell-penetrating circular peptides
|
|
WO2022208489A1
(en)
|
2021-04-02 |
2022-10-06 |
Vilmorin & Cie |
Semi-determinate or determinate growth habit trait in cucurbita
|
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
|
JP2024517607A
(ja)
*
|
2021-04-30 |
2024-04-23 |
メタゲノミ，インク． |
Ｒｕｖｃドメインを有する酵素
|
|
WO2022235929A1
(en)
|
2021-05-05 |
2022-11-10 |
Radius Pharmaceuticals, Inc. |
Animal model having homologous recombination of mouse pth1 receptor
|
|
EP4337263A1
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
|
AU2022271873A1
(en)
|
2021-05-10 |
2024-01-04 |
Entrada Therapeutics, Inc. |
Compositions and methods for intracellular therapeutics
|
|
JP2024518476A
(ja)
|
2021-05-10 |
2024-05-01 |
エントラーダ セラピューティクス，インコーポレイティド |
ｍＲＮＡスプライシングを調節するための組成物及び方法
|
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
EP4347818A2
(en)
|
2021-06-01 |
2024-04-10 |
Arbor Biotechnologies, Inc. |
Gene editing systems comprising a crispr nuclease and uses thereof
|
|
US20240285781A1
(en)
|
2021-06-11 |
2024-08-29 |
GenEdit, Inc. |
Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups
|
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
|
US20240327859A1
(en)
*
|
2021-07-02 |
2024-10-03 |
University Of Maryland, College Park |
Cytidine deaminases and methods of genome editing using the same
|
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
|
EP4377446A1
(en)
|
2021-07-28 |
2024-06-05 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
CA3221517A1
(en)
|
2021-07-30 |
2023-02-02 |
Monika KLOIBER-MAITZ |
Plants with improved digestibility and marker haplotypes
|
|
IL310564A
(en)
|
2021-08-06 |
2024-03-01 |
Vilmorin & Cie |
Resistance to Leveillula Taurica in pepper plant
|
|
CN119452085A
(zh)
|
2021-08-27 |
2025-02-14 |
宏基因组学公司 |
具有ruvc结构域的酶
|
|
US20240368619A1
(en)
|
2021-09-02 |
2024-11-07 |
SESVanderHave NV |
Methods and compositions for ppo herbicide tolerance
|
|
JP7125727B1
(ja)
|
2021-09-07 |
2022-08-25 |
国立大学法人千葉大学 |
核酸配列改変用組成物および核酸配列の標的部位を改変する方法
|
|
JP2024533311A
(ja)
*
|
2021-09-08 |
2024-09-12 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ゲノムを調節するための方法及び組成物
|
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
|
EP4404740A1
(en)
|
2021-09-20 |
2024-07-31 |
Revivicor Inc. |
Multitransgenic pigs comprising ten genetic modifications for xenotransplantation
|
|
EP4596697A3
(en)
|
2021-09-28 |
2025-08-27 |
Acrigen Biosciences |
Compositions and methods for nucleic acid modifications
|
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
EP4412708A4
(en)
*
|
2021-10-05 |
2025-12-03 |
The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone |
SPECIFIC EDITION OF AN ALLELE TO TREAT FUS-INDUCED NEURODEGENERATION
|
|
JP2024538700A
(ja)
|
2021-10-08 |
2024-10-23 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
薬物送達のためのイオン液体
|
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
|
WO2023077148A1
(en)
|
2021-11-01 |
2023-05-04 |
Tome Biosciences, Inc. |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
US20240401074A1
(en)
|
2021-11-15 |
2024-12-05 |
National University Corporation Tottori University |
Method for producing human artificial chromosome vector in human cell
|
|
EP4437096A4
(en)
|
2021-11-24 |
2025-09-24 |
Metagenomi Inc |
ENDONUCLEASE SYSTEMS
|
|
WO2023093862A1
(en)
|
2021-11-26 |
2023-06-01 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
EP4448549A2
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
AU2022420615A1
(en)
|
2021-12-22 |
2024-07-04 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
|
AU2022417615A1
(en)
|
2021-12-23 |
2024-06-27 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250099588A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4479143A1
(en)
|
2022-02-18 |
2024-12-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
|
CA3247638A1
(en)
|
2022-04-06 |
2023-10-12 |
Maria Fardis |
TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CARCINOMA (NSCLC) WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES
|
|
EP4256950A1
(en)
|
2022-04-06 |
2023-10-11 |
Vilmorin et Cie |
Tolerance to cgmmv in cucumber
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
EP4522201A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
WO2023219933A1
(en)
|
2022-05-09 |
2023-11-16 |
Entrada Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acid therapeutics
|
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
CA3251533A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
US20250320254A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Circulating Factors
|
|
EP4533088A2
(en)
|
2022-05-25 |
2025-04-09 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulating genetic drivers
|
|
CA3254044A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
COMPOSITIONS AND MODULATION METHODS OF TUMOR SUPPRESSANTS AND ONCOGENS
|
|
EP4532765A2
(en)
|
2022-05-25 |
2025-04-09 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulation of immune responses
|
|
US20250319115A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Cytokines
|
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
AU2023311964A1
(en)
|
2022-07-18 |
2025-01-30 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
WO2024023734A1
(en)
|
2022-07-26 |
2024-02-01 |
Bit Bio Limited |
MULTI-gRNA GENOME EDITING
|
|
WO2024030930A2
(en)
*
|
2022-08-01 |
2024-02-08 |
The Johns Hopkins University |
Compositions and methods for modifying muller glial cells
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
US20260055146A1
(en)
|
2022-08-24 |
2026-02-26 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250386788A1
(en)
|
2022-08-26 |
2025-12-25 |
KWS SAAT SE & Co. KGaA |
Use of paired genes in hybrid breeding
|
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
|
WO2024050544A2
(en)
|
2022-09-01 |
2024-03-07 |
J.R. Simplot Company |
Enhanced targeted knock-in frequency in host genomes through crispr exonuclease processing
|
|
CA3265262A1
(en)
|
2022-09-01 |
2024-03-07 |
SESVanderHave NV |
PROCESSES AND COMPOSITIONS FOR HERBICIDE TOLERANCE PPO
|
|
EP4583905A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
EP4598944A2
(en)
|
2022-10-03 |
2025-08-13 |
The Regents of the University of California |
Circumventing barriers to hybrid crops from genetically distant crosses
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
JP2025537155A
(ja)
|
2022-11-04 |
2025-11-14 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
KR20250122544A
(ko)
|
2022-11-21 |
2025-08-13 |
이오반스 바이오테라퓨틱스, 인크. |
종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
EP4642225A1
(en)
|
2022-12-29 |
2025-11-05 |
Vilmorin & Cie |
Tomato plants resistant to resistance-breaking tswv strains and corresponding resistance genes
|
|
EP4658061A1
(en)
|
2023-02-01 |
2025-12-10 |
United Beet Seeds |
Beet yellows virus resistance
|
|
WO2024168253A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Delivery of an rna guided recombination system
|
|
WO2024168265A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Aav delivery of rna guided recombination system
|
|
IL322416A
(en)
|
2023-02-15 |
2025-09-01 |
Arbor Biotechnologies Inc |
Gene editing method to inhibit abnormal splicing in stathmin 2 (stmn2) transcription
|
|
WO2024197242A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant vp1 capsid polypeptide and related methods
|
|
US12239091B2
(en)
|
2023-03-27 |
2025-03-04 |
Redsea Science And Technology Inc. |
Tomato plant designated ‘MX20-06’
|
|
WO2024201368A1
(en)
|
2023-03-29 |
2024-10-03 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2024211287A1
(en)
|
2023-04-03 |
2024-10-10 |
Seagen Inc. |
Production cell lines with targeted integration sites
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4698665A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
US20240352485A1
(en)
|
2023-04-19 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for the production of libraries
|
|
WO2024218295A1
(en)
|
2023-04-21 |
2024-10-24 |
Vib Vzw |
Allelic combinations in crops for yield increase
|
|
EP4701406A1
(en)
|
2023-04-28 |
2026-03-04 |
Vilmorin & Cie |
Genetic determinants conferring improved tobrfv resistance
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
EP4713453A1
(en)
|
2023-05-15 |
2026-03-25 |
nChroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236547A1
(en)
|
2023-05-18 |
2024-11-21 |
Inceptor Bio, Llc |
Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2024243340A1
(en)
|
2023-05-23 |
2024-11-28 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
TW202509220A
(zh)
|
2023-06-26 |
2025-03-01 |
美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 |
經工程化之瘧原蟲及相關方法
|
|
WO2025003305A1
(en)
|
2023-06-28 |
2025-01-02 |
Vilmorin & Cie |
Pepper resistance to meloidogyne enterolobii
|
|
CN121548346A
(zh)
|
2023-07-24 |
2026-02-17 |
维尔莫林公司 |
甜瓜对cysdv的抗性
|
|
WO2025030048A2
(en)
|
2023-08-03 |
2025-02-06 |
J.R. Simplot Company |
Fusarium wilt resistance genes
|
|
WO2025046513A1
(en)
|
2023-08-29 |
2025-03-06 |
Inceptor Bio, Llc |
Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
WO2025059215A1
(en)
|
2023-09-12 |
2025-03-20 |
Aadigen, Llc |
Methods and compositions for treating or preventing cancer
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
GB202314578D0
(en)
|
2023-09-22 |
2023-11-08 |
Univ Manchester |
Methods of producing homoplasmic modified plants or parts thereof
|
|
WO2025076141A1
(en)
|
2023-10-03 |
2025-04-10 |
Inari Agriculture Technology, Inc. |
Viral delivery of grna to the scion
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
WO2025111526A1
(en)
|
2023-11-22 |
2025-05-30 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025168705A1
(en)
|
2024-02-08 |
2025-08-14 |
Vib Vzw |
Means and methods for the production of saponins with endosomal escape-enhancing properties
|
|
WO2025171210A1
(en)
|
2024-02-09 |
2025-08-14 |
Arbor Biotechnologies, Inc. |
Compositions and methods for gene editing via homology-mediated end joining
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025186284A1
(en)
|
2024-03-05 |
2025-09-12 |
Vilmorin & Cie |
Increased yield in cucumber
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025240947A1
(en)
|
2024-05-17 |
2025-11-20 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
US20250382627A1
(en)
|
2024-06-13 |
2025-12-18 |
J.R. Simplot Company |
Engineering remontant flowering in rosaceae
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|
|
WO2026015832A2
(en)
|
2024-07-12 |
2026-01-15 |
Arbor Biotechnologies, Inc. |
Reverse transcriptases and gene editing systems comprising such
|
|
WO2026015829A2
(en)
|
2024-07-12 |
2026-01-15 |
Arbor Biotechnologies, Inc. |
Small reverse transcriptases and gene editing systems comprising such
|
|
WO2026017833A1
(en)
|
2024-07-17 |
2026-01-22 |
Vilmorin & Cie |
Tswv-resistant pepper
|
|
US20260043035A1
(en)
|
2024-08-08 |
2026-02-12 |
Invaio Sciences, Inc. |
Nature-derived lipid particles for use in agriculture
|
|
WO2026047626A1
(en)
|
2024-08-30 |
2026-03-05 |
Inceptor Bio, Llc |
Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
|